Skip to main content

Clene, Inc. (CLNN)

NASDAQ: CLNN · IEX Real-Time Price · USD
6.09 0.00 (0.00%)
Oct 21, 2021 4:00 PM EDT - Market open
Market Cap362.80M
Revenue (ttm)541,000
Net Income (ttm)-52.62M
Shares Out61.17M
EPS (ttm)-1.34
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume4,438
Open-
Previous Close6.09
Day's Range5.73 - 6.20
52-Week Range5.65 - 17.82
Betan/a
Analystsn/a
Price Targetn/a
Est. Earnings DateNov 8, 2021

About CLNN

Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean surfaced nanotechnology (CSN) therapeutics. The company has a nanotechnology drug suspension; and engages in the development and commercialization of dietary supplements. Its lead drug is CNM-Au8, which is being studied in various clinical trials, including a Phase 2 study for the treatment of stable multiple sclerosis; a Phase 2 biomarker study in Parkinson's; and Phase 2 and Phase 3 trials to investigate the potenti...

IndustryBiotechnology
Founded2012
Employees63
Stock ExchangeNASDAQ
Ticker SymbolCLNN
Full Company Profile

Financial Performance

Financial Statements

News

Clene Announces Initiation of a Second FDA Expanded Access Program with CNM-Au8 for People Living with Amyotrophic La...

SALT LAKE CITY, Sept. 23, 2021 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ: CLNN) along with its subsidiaries “Clene” and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharmaceuti...

4 weeks ago - GlobeNewsWire

Clene Presents Phase 2 CNM-Au8 CNS Target Engagement Data at the International Parkinson and Movement Disorder Societ...

CNM-Au8® , a catalytically active gold nanocrystal suspension, significantly improved brain energetic metabolism in Parkinson's patients CNM-Au8® , a catalytically active gold nanocrystal suspension, si...

1 month ago - GlobeNewsWire

Clene Completes Final Patient Visit in Phase 2 RESCUE-ALS Study: Topline Data Readout Expected Q4 2021

SALT LAKE CITY, Sept. 09, 2021 (GLOBE NEWSWIRE) --  Clene Inc. (NASDAQ: CLNN) along with its subsidiaries “Clene” and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharmaceut...

1 month ago - GlobeNewsWire

Clene Nanomedicine to Present at Upcoming Virtual Investor Conferences

SALT LAKE CITY, Aug. 31, 2021 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ: CLNN) along with its subsidiaries “Clene” and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharmaceutic...

1 month ago - GlobeNewsWire

Clene Reports Second Quarter 2021 Operating and Financial Highlights

Phase 2 REPAIR program demonstrated statistically significant improvements in brain energetic metabolism with CNM-Au8®, a gold nanocrystal suspension

2 months ago - GlobeNewsWire

Clene's Stock Gain As Its Nanotherapeutic Improves Energy Production, Brain Utilization In Patients With Parkinson's,...

Clene Inc (NASDAQ: CLNN) has shared positive top-line results from the Phase 2 REPAIR trials investigating the improvement of brain energetic metabolism in Parkinson's disease (PD) and multiple sclerosi...

2 months ago - Benzinga

Clene Reports Positive Top-line Results from its Phase 2 REPAIR Clinical Trials in Parkinson's Disease and Multiple S...

Achieved a statistically significant increase in the Phase 2 program's primary endpoint  (mean change in brain NAD+/NADH ratio)

2 months ago - GlobeNewsWire

Clene to Present at Canaccord Genuity's Annual Growth Conference

SALT LAKE CITY, Aug. 03, 2021 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ: CLNN) along with its subsidiaries “Clene” and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharmaceutic...

2 months ago - GlobeNewsWire

7 Highly Shorted Stocks Heading Into Q3 2021

If you're thinking about going for the ultimate contrarian trade, here is a list of the most heavily shorted stocks. The post 7 Highly Shorted Stocks Heading Into Q3 2021 appeared first on InvestorPlace.

3 months ago - InvestorPlace

7 Short-Squeeze Stocks To Buy In July For Contrarian Investors

These shares are among the stocks with the most short sell positions The post 7 Short-Squeeze Stocks To Buy In July For Contrarian Investors appeared first on InvestorPlace. More From InvestorPlace Stoc...

Other symbols:AMCBBCARVGDRXGMEIRBT
3 months ago - InvestorPlace

Clene Added to Membership of Russell 2000® Index

SALT LAKE CITY, June 28, 2021 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharmaceu...

3 months ago - GlobeNewsWire

Clene Nanomedicine Receives Catalyst Award for Healthy Longevity from U.S. National Academy of Medicine to Accelerate...

International award will fund preclinical study of CNM-Au8 nanocatalysis for the improvement of human health and lifespan in the contexts of aging and Alzheimer's disease

5 months ago - GlobeNewsWire

Clene Nanomedicine Presents Updated Blinded Efficacy Data from Ongoing Phase 2 RESCUE-ALS Study at the ENCALS 2021 An...

Preliminary blinded efficacy data suggest CNM-Au8 may have the potential for neuro-repair in amyotrophic lateral sclerosis (ALS) patients

5 months ago - GlobeNewsWire

Clene Reports First Quarter 2021 Operating and Financial Highlights

Interim Phase 2 data indicate that CNM-Au8 has a homeostatic effect on brain bioenergetics and support its potential to drive meaningful neurological functional improvements in MS patients

5 months ago - GlobeNewsWire

Clene Nanomedicine Receives Two Patent Notice of Allowances in the U.S. for Its Platform Nanocrystal Therapeutic Tech...

IP portfolio now totals over 160 patents issued, allowed, and pending IP portfolio now totals over 160 patents issued, allowed, and pending

5 months ago - GlobeNewsWire

Clene Reports Full Year 2020 Operating and Financial Highlights

Interim Phase 2 data indicate that CNM-Au8 has a homeostatic effect on brain bioenergetics

6 months ago - GlobeNewsWire

Clene Nanomedicine Announces Upcoming Presentations at the Maxim Group LLC Inaugural 2021 Emerging Growth Virtual Con...

SALT LAKE CITY, March 10, 2021 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharmace...

7 months ago - GlobeNewsWire

Clene Nanomedicine Announces Achievement of 50% Enrollment in the Phase 3 HEALEY ALS Platform Trial

World's first ALS platform trial led by Mass General Hospital and conducted at NEALS centers throughout the United States is a registration trial World's first ALS platform trial led by Mass General Hos...

7 months ago - GlobeNewsWire

Clene Nanomedicine to Present at Upcoming Virtual Investor Conferences

SALT LAKE CITY, March 03, 2021 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ: CLNN) (along with its subsidiaries, “Clene”) today announced that its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-...

7 months ago - GlobeNewsWire

Clene's Lead Candidate Shows Improvement In Functional Scores In Multiple Sclerosis Studies

Clene Inc (NASDAQ: CLNN) has reported updated blinded interim data from the VISIONARY-MS Phase 2 study evaluating the efficacy and safety of lead drug candidate, CNM-Au8, in multiple sclerosis. The anal...

7 months ago - Benzinga

Clene Nanomedicine Presents Updated Interim Data from Phase 2 Multiple Sclerosis Programs at ACTRIMS Forum 2021

SALT LAKE CITY, Feb. 25, 2021 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ: CLNN) (along with its subsidiaries, “Clene”) today announced that its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-s...

7 months ago - GlobeNewsWire

Clene Nanomedicine to Present Updated Interim Data from Phase 2 Multiple Sclerosis Programs at ACTRIMS Forum 2021

SALT LAKE CITY, Feb. 19, 2021 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharmaceu...

8 months ago - GlobeNewsWire

Clene Nanomedicine Initiates Phase 2 Study of CNM-ZnAg for Patients with COVID-19

SALT LAKE CITY, Feb. 16, 2021 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ: CLNN) (along with its subsidiaries, “Clene”) today announced that its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-s...

8 months ago - GlobeNewsWire

Why Clene Stock Skyrocketed Today

One Wall Street analyst has high hopes for the biopharmaceutical company.

8 months ago - The Motley Fool

Clene Nanomedicine Closes Merger with Tottenham Acquisition I Limited and Provides Corporate Update

Clene is a clinical-stage biopharmaceutical company focused on the development of unique therapeutics for neurodegenerative diseases. Clene has innovated a novel nanotechnology drug platform for the dev...

9 months ago - GlobeNewsWire